A once-weekly injectable glucose-dependent insulinotropic polypeptide/GLP-1 dual agonist conferred up to 14.7% weight loss at 13 weeks for adults with overweight or obesity, according to findings from ...

BAAR, CH / / January 19, 2026 / PolyPeptide Group AG (SIX:PPGN), a specialized global CDMO for peptide-based active pharmaceutical ingredients, today announced the successful closing of its ...

Scientists led by Dr. Timo Müller from Helmholtz Munich and the German Center for Diabetes Research (DZD) have now discovered that glucose-dependent insulinotropic polypeptide (GIP) decreases body ...

On Wednesday, Barclays (LON:BARC) initiated coverage on PolyPeptide Group AG (SIX:PPGN:SW) stock with an Overweight rating and a price target of CHF 40.00. The firm anticipates a return to positive ...

Fintel reports that on January 26, 2026, BERENBERG upgraded their outlook for PolyPeptide Group (OTCPK:PLYGF) from Hold to Buy. What is the Fund Sentiment? There are 34 funds or institutions reporting ...

This collaboration aims to enhance supply chain resilience, improve operational efficiency and accelerate readiness for the rapidly expanding global peptides market. This partnership strengthens LMS ...

The collaboration between Donaldson and PolyPeptide marks a milestone in the pharmaceutical industry's pursuit of environmentally friendly manufacturing practices. By leveraging Donaldson's experience ...

Investing.com -- PolyPeptide Group AG on Monday reported revenue of €389 million for the financial year 2025, representing a growth rate of 15.6% compared to the previous year.

There is new research into a new battery technology platform that is completely metal-free. This new battery technology platform utilizes a polypeptide organic radical construction. Almost all Li-ion ...